- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Vitrafy Life Sciences Q2 FY26 slides highlight animal health deal and U.S. expansion | 2 | Investing.com | ||
| VITRAFY LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| Mi | VITRAFY LIFE SCIENCES LIMITED: Vitrafy Q2 FY26 Investor Briefing | 2 | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Initial Director's Interest Notice | - | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Appointment of Independent Non-Executive Director | - | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Change in substantial holding from RYD | - | ASX | ||
| 14.01. | VITRAFY LIFE SCIENCES LIMITED: IMV Strategic Commercial Agreement Investor Briefing | - | ASX | ||
| 14.01. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy Enters Strategic Commercial Agreement with IMV | - | ASX | ||
| 14.01. | VITRAFY LIFE SCIENCES LIMITED: IMV Strategic Partnership Investor Presentation | - | ASX | ||
| 14.12.25 | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 14.12.25 | VITRAFY LIFE SCIENCES LIMITED: Notification regarding unquoted securities - VFY | - | ASX | ||
| 21.11.25 | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 21.11.25 | VITRAFY LIFE SCIENCES LIMITED: Notification of cessation of securities - VFY | 2 | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: Final Director's Interest Notices | - | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: Application for quotation of securities - VFY | - | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: Results of 2025 Annual General Meeting | - | ASX | ||
| 20.11.25 | VITRAFY LIFE SCIENCES LIMITED: 2025 Annual General Meeting Chair Address & Presentation | 1 | ASX | ||
| 19.11.25 | VITRAFY LIFE SCIENCES LIMITED: Bell Potter Healthcare Conference Presentation | - | ASX | ||
| 07.11.25 | VITRAFY LIFE SCIENCES LIMITED: Release of Securities from Mandatory Escrow | - | ASX | ||
| 24.10.25 | ASX Quarterly Health Wrap: Lumos lands US$317m deal as ReNerve and Vitrafy hit key milestones | 1 | Stockhead | ||
| 23.10.25 | Vitrafy Life Sciences Q1 FY26 slides: VCU2 delivery milestone as commercialization accelerates | 2 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | Qiagen: Das ist gewagt! | Dass die sonst zu den ruhigen DAX-Aktien gehörende Qiagen auf einmal in kurzer Zeit einen Kurssprung von in der Spitze 21 Prozent hinlegt, zieht Aufmerksamkeit auf sich. Aber könnte man der Aktie neben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,30 | +0,01 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,08 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab | ||
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,58 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| ADMA BIOLOGICS | 17,300 | +1,70 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
VITRAFY LIFE SCIENCES LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITRAFY LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.